908 Devices Launches Data Analysis Visualization Tool for REBEL At-line Cell Culture Media Analyzer
New tool is built on the JMP statistical software package
REBEL provides at-line measurement of amino acids, vitamins and other metabolites that are essential to cell growth and viability in the development of biotherapeutics. Data from the REBEL is generated as a quantitative report. With the new add-in tool, process development scientists can easily visualize amino acid depletion or accumulation trends over the course of time within a bioreactor, leading to improved process understanding and facilitating adjustments to the media feed strategy.
“We’re excited to provide our REBEL users with a tool that helps them remove data analysis and visualization bottlenecks,” said Dr. Graziella Piras, Senior Director of Life Science Strategic Marketing at 908 Devices. “The ability to measure samples in near real-time and to quickly visualize the data provides our biopharmaceutical customers with actionable information to accelerate their development process.”
Existing REBEL users with access to the JMP statistical software package can download the add-in tool from the 908 Devices customer support portal. To learn more about the REBEL and the visualization tool, view this BPI: Ask the Expert webinar. To obtain a JMP software trial, visit http://www.jmp.com/908webinar.
About the REBEL analyzer
REBEL is a first-of-its-kind fresh and spent media analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line. Key benefits include:
- Efficiency – minimal sample preparation and tiny volume requirements
- Real-time data tracking – quantitate over 30 key media nutrients in <10 minutes
- Small and simple – versatile design valued by users across many applications
For more information, visit www.908devices.com.
JMP is a registered trademark of JMP Statistical Discovery LLC. REBEL is a registered trademark of 908 Devices Inc.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Source: 908 Devices Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005303/en/
Media
Barbara Russo
brusso@908devices.com
Investors
Carrie Mendivil
IR@908devices.com
Source: 908 Devices Inc
